Trichomoniasis
Summary
Trichomoniasis ("Trich") is the most common curable sexually transmitted infection (STI) worldwide, caused by the flagellated protozoan parasite Trichomonas vaginalis. It affects approximately 156 million new cases per year globally (WHO). The infection primarily involves the urogenital tract (Vagina, urethra, paraurethral glands) and is transmitted through unprotected sexual intercourse. Women are more commonly symptomatic (50-70%) presenting with frothy, yellow-green, malodorous vaginal discharge, vulval irritation, and dysuria. Men are often asymptomatic carriers. The pathognomonic sign is "strawberry cervix" (colpitis macularis) – punctate red hemorrhages on the cervix. Diagnosis is by NAAT (Gold standard) or wet mount microscopy showing motile flagellated protozoa. Treatment is with metronidazole (400mg BD for 5-7 days or 2g stat). Partner notification and simultaneous treatment are essential. Complications include increased HIV acquisition/transmission risk and adverse pregnancy outcomes (Preterm birth, Low birth weight). Trichomoniasis frequently co-exists with other STIs (Chlamydia, Gonorrhoea) – always screen for co-infections. [1,2,3]
Key Facts
| Fact | Value |
|---|---|
| Definition | STI caused by flagellated protozoan Trichomonas vaginalis |
| Global Incidence | ~156 million new cases/year (WHO) |
| Organism | Protozoan parasite (NOT bacteria or virus) |
| Transmission | Unprotected sexual intercourse |
| Symptomatic Women | 50-70% |
| Symptomatic Men | 10-30% |
| Classic Discharge | Frothy, Yellow-green, Malodorous ("fishy") |
| Pathognomonic Sign | Strawberry cervix (Colpitis macularis) |
| Diagnosis Gold Standard | NAAT |
| First-Line Treatment | Metronidazole 400mg BD for 5-7 days |
| Alternative | Metronidazole 2g stat (Single dose) |
| Cure Rate | More than 90% |
| Key Caution | Avoid alcohol (Disulfiram-like reaction) |
| HIV Risk | Increases acquisition and transmission |
| Pregnancy Risk | Preterm birth, Low birth weight |
| Co-infection Rate | High with Chlamydia, Gonorrhoea |
| Test of Cure | Not routine; Indicated if persistent symptoms/Pregnancy |
Clinical Pearls
"Most Common Curable STI Worldwide": 156 million cases/year. Often underdiagnosed compared to Chlamydia.
"Protozoan, NOT Bacteria": Trichomonas is a flagellated protozoan. It does not respond to penicillin or doxycycline. It needs nitroimidazoles.
"Strawberry Cervix": Pathognomonic sign, But only seen in ~2% with naked eye. Requires colposcopy to see in 50%.
"Frothy, Fishy, Yellow-Green": The classic triad description for exams. If you hear "Frothy", think Trich.
"Men Carry, Women Suffer": Men are often asymptomatic reservoirs who reinfect their treated female partners.
"Metronidazole is Curative": 400mg BD for 5-7 days is the Gold Standard. Single 2g dose is an alternative but has higher failure rates in women.
"No Alcohol Rule": Disulfiram-like (Antabuse) reaction is severe. Counsel every patient to avoid alcohol for 48 hours.
"Partner Treatment Essential": You treat the couple, not the individual. Without partner treatment, reinfection is inevitable.
"Screen for Co-infections": You are never "just" treating Trichomonas. Always check for Chlamydia, Gonorrhoea, Syphilis, and HIV.
"HIV Link": Trichomonas increases HIV acquisition by 1.5-2x due to recruitment of inflammatory cells (CD4 targets) to the mucosa.
"Pregnancy Matters": Associated with preterm labour and low birth weight. Symptomatic pregnant women must be treated.
"NAAT is Gold Standard": Sensitivity >95%. Wet mount is good for immediate diagnosis but misses 40% of cases.
"pH is HIGH": Vaginal pH is almost always >4.5 (usually 5.0-6.0). If pH is normal (Less than 4.5), Trich is unlikely (think Candida).
Diagnostic Criteria Summary
| Criteria | Finding | Sensitivity |
|---|---|---|
| Symptoms | Frothy discharge, Dysuria | Low (Non-specific) |
| Signs | Strawberry Cervix | Very Low (2%) but Specific |
| pH | > 4.5 | High (But non-specific, seen in BV) |
| Wet Mount | Motile Flagellated Protozoa | 50-60% (Moderate) |
| Culture | Growth in liquid medium | 75-95% (High) |
| NAAT | Positive DNA/RNA amplification | >95-98% (Gold Standard) |
Why This Matters Clinically
Trichomoniasis is more than just a nuisance infection.
- Public Health: It is a major driver of the HIV epidemic, facilitating transmission.
- Reproductive Health: It causes adverse pregnancy outcomes (preterm birth) and pelvic inflammatory disease (PID).
- Quality of Life: The symptoms can be distressing and debilitating for women.
- Clinical Skills: Identifying it requires specific skills (microscopy, specific history questions) and excellent communication for partner notification.
- Antibiotic Stewardship: Using the right drug (metronidazole) at the right dose prevents resistance.
Historical Context
First described by Alfred Donné in 1836, who observed "animalcules" in purulent discharge. It was long considered a harmless commensal until the mid-20th century when its pathogenicity was confirmed. The introduction of metronidazole in 1960 revolutionised treatment, transforming it from a chronic affliction to a curable condition.
Trichomoniasis is the most common curable STI globally but is frequently underdiagnosed, Especially in asymptomatic men who act as reservoirs. It has significant public health implications due to its association with increased HIV transmission (Inflammation facilitates viral entry), Adverse pregnancy outcomes, And high rates of co-infection with other STIs. Effective management requires treatment of both the index patient AND sexual partners to break the transmission cycle. This condition is commonly examined in OSCE stations focusing on STI history, Discharge assessment, And counselling around alcohol avoidance with metronidazole.
Key Principle
[!NOTE] Trichomoniasis is the most common curable STI worldwide with ~156 million new cases/year. It is underdiagnosed because many cases (Especially in men) are asymptomatic. It has significant public health implications for HIV transmission and pregnancy outcomes.
Incidence & Prevalence
| Measure | Value | Notes |
|---|---|---|
| Global Incidence | ~156 million/year | WHO estimate (2016) |
| Global Prevalence | ~5.3% in women | 276 million infected |
| Global Prevalence (Men) | ~1.4% | Often asymptomatic |
| UK Prevalence | 1-2% | Lower prevalence |
| US Prevalence | 2-3% (Women) | Higher in certain populations |
| Prevalence (High-Risk Populations) | 10-30% | Sexual health clinics, Prisons |
| Prevalence (Antenatal) | 3-5% | Varies by region |
| Prevalence (HIV-positive Women) | 10-30% | Higher rates |
Global Burden by Region
| Region | Estimated Prevalence | Notes |
|---|---|---|
| Sub-Saharan Africa | 10-20% | Highest global burden |
| Latin America | 5-10% | Significant burden |
| Asian-Pacific | 2-5% | Variable |
| Eastern Europe | 3-5% | Limited data |
| Western Europe | 1-3% | Lower prevalence |
| North America | 2-4% | Racial disparities |
Demographics - Detailed
| Factor | Details | Clinical Significance |
|---|---|---|
| Age | Peak 16-35 years | Sexually active age |
| Highest Risk Age | 16-24 years | Screen actively |
| Sex | Females more symptomatic | Males often asymptomatic carriers |
| Female:Male Ratio (Symptomatic) | 3:1 | Women present more often |
| Ethnicity | Higher in Black populations (US) | May reflect healthcare access |
| Socioeconomic | Higher in lower SES | Access barriers |
| Sexual Behaviour | Multiple partners, Unprotected sex | Key risk |
| Relationship Status | Single, Multiple partners | Higher risk |
Healthcare Utilisation Impact
| Factor | Impact |
|---|---|
| Underdiagnosis | Many cases missed (Especially men) |
| Screening Rate | Low in many settings |
| Treatment Rate | High when diagnosed |
| Reinfection Rate | 5-15% within 3 months |
| Partner Treatment Rate | Often inadequate |
Risk Factors - Detailed
High-Risk Groups:
| Group | Risk Factor |
|---|---|
| Sex Workers | Occupational exposure |
| People Who Inject Drugs | Risk behaviours |
| Incarcerated Populations | High-risk environment |
| Homeless Populations | Healthcare access |
| MSM (Men Who Have Sex With Men) | Lower risk (Uncommon in anal sex) |
| Young Adults (16-24) | High prevalence age |
Predisposing Factors:
| Factor | Mechanism |
|---|---|
| Unprotected Sexual Intercourse | Primary transmission route |
| Multiple Sexual Partners | Increased exposure |
| New Sexual Partner | Higher risk |
| History of STIs | Marker of risk behaviour |
| Concurrent STIs | Co-infection common |
| Non-use of Barrier Contraception | Condoms protective |
| Lower Socioeconomic Status | Healthcare access |
| Incarceration | High-risk environment |
| Sex Work | Occupational risk |
| Substance Use | Risk behaviours |
| Vaginal Douching | Alters flora |
Co-infections - Detailed
| Co-infection | Prevalence | Clinical Significance |
|---|---|---|
| Chlamydia trachomatis | 10-20% | Always screen, Similar treatment timing |
| Neisseria gonorrhoeae | 10-15% | Always screen, Similar treatment timing |
| HIV | Variable | Trichomonas increases HIV acquisition 1.5-2x |
| Bacterial Vaginosis | High (30-50%) | Overlapping flora, Similar pH abnormality |
| HPV | Variable | May increase cervical disease progression |
| Syphilis | 1-5% | Screen as part of full STI screen |
| Herpes Simplex | Variable | May coexist |
Public Health Implications
| Issue | Impact |
|---|---|
| HIV Transmission | 1.5-2x increased risk |
| Pregnancy Outcomes | Preterm birth, Low birth weight |
| Healthcare Costs | Significant when complications occur |
| Underdiagnosis | Reservoir of infection |
| Partner Notification Challenges | Reinfection common |
Key Principle
[!NOTE] Trichomonas vaginalis is an extracellular, flagellated protozoan parasite. It is an obligate parasite (cannot survive long outside the host). Pathogenesis involves adhesion to the cervicovaginal epithelium, cytotoxicity, and a robust inflammatory response (neutrophil influx) which characterises the clinical discharge and facilitates HIV transmission.
Organism Characteristics - Detailed
| Feature | Details | Clinical Relevance |
|---|---|---|
| Classification | Protozoan (Flagellate) | Eukaryotic, Anaerobic |
| Morphology | Pear-shaped (Trophozoite) | Diagnosable on microscopy |
| Size | 10-20µm (Similar to WBC) | Can be confused with WBCs if not motile |
| Motility | Jerky, twitching, tumbling | Diagnostic feature on wet mount |
| Flagella | 4 anterior, 1 posterior | Undulating membrane aids motility |
| Life Cycle | No cyst form | Only exists as trophozoite |
| Replication | Binary fission | Rapid multiplication |
| Metabolism | Anaerobic (Hydrogenosome) | Target for metronidazole |
| Survival | Fragile outside host | Requires moisture and specific pH |
Virulence Factors
| Factor | Function |
|---|---|
| Adhesins (AP65, AP51, AP33) | Mediates attachment to vaginal epithelial cells |
| Cysteine Proteases | Degrades host proteins (IgA, IgG), ECM, and mucin |
| Cell-Detaching Factors | Causes epithelial cells to detach and die |
| Hemolysins | Lyses Red Blood Cells (Source of iron/lipids) |
| Lipophosphoglycan (LPG) | Surface molecule involved in adhesion |
Pathophysiology Steps - Detailed
Step 1: Transmission and Colonisation
- Entry via sexual intercourse (inoculum).
- Flagella aid movement through vaginal mucus.
- pH Preference: Thrives in higher pH (5.0-6.0). Normal vaginal acidity (Less than 4.5) is protective.
- Menstrual blood (pH 7.4) facilitates establishment (hence symptoms often post-menses).
Step 2: Adhesion (Contact-Dependent)
- Parasite transforms from free-swimming to amoeboid form upon contact.
- Adhesins bind to laminin and fibronectin on host epithelium.
- This "kiss of death" contact is required for cytotoxicity.
Step 3: Cytotoxicity and Epithelial Damage
- Micropinocytosis: Parasite rarely ingests host cells but "nibbles" them.
- Release of perforin-like proteins and proteases.
- Induction of host cell apoptosis and necrosis.
- Disruption of epithelial barrier integrity.
Step 4: The Inflammatory Response (The "Purulent" Phase)
- Host epithelial cells release chemokines (IL-8).
- Massive influx of Neutrophils (PMNs) into the vaginal lumen.
- Discharge: The frothy, yellow-green discharge is largely composed of neutrophils and dead epithelial cells.
- Free Radical Release: Neutrophils release ROS, causing further tissue irritation.
Step 5: Impact on Vaginal Microbiome
- T. vaginalis correlates with loss of healthy Lactobacillus.
- Synergistic relationship with BV-associated bacteria (Gardnerella, Mycoplasma).
- Both thrive in anaerobic, high pH environment.
- The high pH neutralises the protective effect of lactic acid.
Step 6: "Strawberry Cervix" Formation
- Colpitis Macularis: Local dilation of capillaries and punctate hemorrhages.
- Caused by high local concentration of organisms and inflammatory mediators.
- Gives the mottled red appearance.
Immune Evasion Mechanisms
| Mechanism | How it Works |
|---|---|
| Antigenic Variation | Changes surface proteins to evade antibodies |
| Protease Secretion | Degrades host immunoglobulins (IgA, IgG) |
| Complement Evasion | Resists lysis by alternate complement pathway |
| Phagocytosis Escape | Too large to be easily phagocytosed by neutrophils |
| Molecular Mimicry | Surface proteins mimic host proteins |
The HIV Connection (Crucial Mechanism)
Trichomoniasis increases HIV transmission risk by 2-fold via:
- Epithelial Breach: Micro-ulcerations provide entry portal for virus.
- Target Cell Recruitment: Inflammation recruits CD4+ T-cells and Macrophages (HIV targets) to the genital tract.
- Viral Shedding: Increase HIV RNA shedding in co-infected individuals.
- Flora Disruption: Loss of protective H2O2-producing lactobacilli.
Pathophysiology Diagram

Pathophysiology Diagram

Key Principle
[!NOTE] Trichomoniasis Presentation:
- Women: 50-70% symptomatic. Classic triad: Frothy yellow-green discharge, Vulval irritation, Dysuria.
- Men: 70-90% asymptomatic. Key reservoir for transmission.
- Pathognomonic: Strawberry cervix (Colpitis macularis) - Specific but insensitive.
Incubation and Course
| Feature | Details |
|---|---|
| Incubation Period | 4-28 days (Range 2 days to 3 months) |
| Onset | Can be sudden or insidious |
| Course | Persistent if untreated (Can last years) |
| Symptom Fluctuation | Symptoms may worsen during menstruation (Higher pH) |
| Asymptomatic Interval | Can be asymptomatic for years before symptoms appear |
Presentation by Sex - Detailed
Women (Symptomatic in 50-70%):
| Symptom | Description | Frequency | Clinical Note |
|---|---|---|---|
| Vaginal Discharge | Profuse, Frothy, Yellow-green, Malodorous ("fishy") | 50-75% | Can be confused with BV |
| Vulval Irritation | Itching (Pruritus), Soreness, Burning | 30-50% | Can be severe |
| Dysuria | Pain on urination (External due to vulvitis) | 30% | "Stinging" sensation |
| Dyspareunia | Superficial pain during intercourse | 20-30% | Due to inflammation |
| Lower Abdominal Pain | Mild, Dull ache | 10-20% | If severe, exclude PID |
| Post-Coital Bleeding | Spotting after sex | Less common | Due to cervicitis |
Men (Asymptomatic in 70-90%):
| Symptom | Description | Frequency | Clinical Note |
|---|---|---|---|
| Asymptomatic | No symptoms | 70-90% | "Silent carrier" |
| Urethral Discharge | Scant, Clear/White, Mucoid | 5-15% | Often morning only |
| Urethral Irritation | Itching inside penis, Mild burning | 5-15% | "Tickling" sensation |
| Dysuria | Mild pain on urination | 5-10% | Need to exclude Chlamydia/Gonorrhoea |
| Prostatitis | Perineal pain, Ejaculatory pain | Less than 5% | Chronic reservoir |
| Balanitis | Inflammation of glans | Rare | In uncircumcised men |
Differential Diagnosis - Vaginal Discharge
| Feature | Trichomoniasis | Bacterial Vaginosis (BV) | Vulvovaginal Candidiasis (Thrush) | Normal Discharge |
|---|---|---|---|---|
| Primary Complaint | Discharge + Irritation | Malodorous Discharge | Itching +++ | None |
| Discharge Colour | Yellow-green | Grey-white | White | Clear/White |
| Discharge Consistency | Frothy, Purulent | Thin, Homogeneous, Watery | Thick, Curdy ("Cottage Cheese") | Mucoid, Variable |
| Odour | Fishy (Offensive) | Fishy (Amine) | None / Yeasty | Non-offensive |
| Vaginal pH | More than 4.5 (High) | More than 4.5 (High) | Less than 4.5 (Normal) | Less than 4.5 |
| Inflammation | Present (Erythema) | Absent (Non-inflammatory) | Present (Erythema, Fissures) | Absent |
| Whiff Test | Positive | Positive | Negative | Negative |
| Microscopy | Motile protozoa | Clue cells | Hyphae/Spores | Epithelial cells |
Red Flags requiring Urgent/Specialist Assessment
| Red Flag | Clinical Reasoning | Immediate Action |
|---|---|---|
| Pregnancy | Risk of Preterm Labour (PTL) and Premature Rupture of Membranes (PROM). | Urgent Treatment. Do not delay. Avoid high-dose stat regimen in 1st trimester if possible. |
| Pelvic Pain / Deep Dyspareunia | Suggests ascending infection (PID). T. vaginalis can facilitate bacterial ascent. | PID Protocol. Cover for Gonorrhoea, Chlamydia, Anaerobes. Add Metronidazole. |
| Systemic Symptoms (Fever, Malaise) | Complicated infection (PID, Tubo-ovarian abscess) or Disseminated Gonorrhoea. | Admit or Urgent GUM referral. septic screen. |
| Cervical Motion Tenderness | Hallway sign of PID ("Chandelier Sign"). | Treat for PID immediately. |
| HIV Positive | Increased viral shedding; Higher risk of treatment failure. | Treat promptly. Ensure 7-day course (Single dose has higher failure rate in HIV). |
| Pre-pubertal Child | Safeguarding Red Flag. Trichomonas is almost exclusively sexually transmitted. | Safeguarding Referral. Paediatric assessment. Do not simply treat. |
| Recurrent Infection | Reinfection (partner) or Resistance. | Detailed sexual history. Partner check. Culture for resistance. |
| Male with Dysuria/Discharge | Rare. Symptoms in men usually mean high organism load or co-infection. | Screen for all STIs. Check for epididymo-orchitis. |
[!CAUTION] Safeguarding Alert: Diagnosis of Trichomonas vaginalis in a child is a definitive marker of sexual abuse until proven otherwise, as it is not commensal and does not survive in the environment.
Assessment of Complications (Algorithm)
| Finding | Suggests | Action |
|---|---|---|
| Cervical Motion Tenderness | PID | Treat for PID (Ceftriaxone + Doxy + Metro) |
| Urethral Discharge (Men) | Urethritis | Gram stain, NAAT for CT/NG/MG/TV |
| Testicular Pain | Epididymo-orchitis | Screen and treat |
| Joint Pain / Rash | Reactive Arthritis (Reiters) | Rare complication of STIs |
| Abdominal Pain (RUQ) | Fitz-Hugh-Curtis Syndrome | Rare peri-hepatitis (usually Chlamydia, possible with others) |
Key Principle
[!NOTE] Detailed examination is crucial not just for diagnosis, but for assessing complications (like PID) and co-infections (like Herpes or Syphilis).
Always examine:
> 1. Abdomen (Tenderness) > 2. External Genitalia (Ulcers, Dermatitis) > 3. Speculum (Discharge, Cervicitis) > 4. Bimanual (Tenderness - PID check)
Examination Protocol: Women
1. Abdominal Examination:
- Palpate lower abdomen.
- Tenderness in iliac fossae suggests Pelvic Inflammatory Disease (PID) or other pathology.
2. External Genital Inspection:
- Vulvitis: Look for erythema and oedema of the labia and introitus.
- Dermatitis: Excoriations from scratching (itch).
- Discharge: May be visible at the introitus (yellow/green).
- Other STIs: Check for Herpes ulcers, Syphilis chancres, Warts.
3. Speculum Examination (Crucial Step):
- Discharge: Look for pooling in the posterior fornix.
- Classic: Frothy, Yellow-green, Bubbles visible.
- Note: Mucopurulent discharge from the OS suggests Gonorrhoea/Chlamydia.
- Vaginal Walls: Erythematous, "Angry" appearance.
- Cervix:
- "Strawberry Cervix" (Colpitis Macularis): Punctate petechial hemorrhages.
- Friability: Bleeds easily on contact (swabbing).
- pH Testing: Touch indicator paper to lateral vaginal wall.
4. Bimanual Examination:
- Goal: Exclude PID / Upper Genital Tract Infection.
- Cervical Motion Tenderness (CMT): "Chandelier sign" - pain on moving cervix.
- Adnexal Tenderness: Pain in ovarian regions.
- Uterine Tenderness: Pain on compressing uterus.
- If any of these are positive, treat for PID immediately.
Examination Protocol: Men
1. Inspection:
- Urethral Meatus: Check for discharge (may need to "milk" the urethra).
- Glans/Prepuce: Check for Balanitis (inflammation), Ulcers, Warts.
2. Palpation:
- Testicles: Check for tenderness/swelling (Epididymo-orchitis).
- Epididymis: Tenderness suggests ascending infection.
3. Digital Rectal Exam (DRE):
- Only if prostatitis suspected (Perineal pain, dysuria +++).
- Boggy, tender prostate.
Documentation Checklist (Medico-legal)
| Item | Status | Example Entry |
|---|---|---|
| Consent | Required | "Verbal consent obtained for examination" |
| Chaperone | Mandatory | "Chaperoned by Nurse X" |
| Abdomen | Findings | "Soft, non-tender" |
| External | Findings | "Vulva erythematous, no ulcers" |
| Speculum | Findings | "Cervix visualised, strawberry appearance, frothy green discharge" |
| Bimanual | Findings | "No cervical motion tenderness, no adnexal masses" |
| Samples | Swabs taken | "HVS (wet mount) + NAAT taken" |
"Use of the Speculum" - Clinical Tips
[!TIP] Optimising the Exam: > 1. Warm the speculum: Cold metal causes muscle spasm. > 2. Lubrication: Use water or minimal water-soluble lube (excess lube can interfere with slides/swabs). > 3. Angle: Insert at 45 degrees, then rotate to horizontal. > 4. Visualize: Ensure you can see the cervix fully to rule out "Strawberry" spots. > 5. Swab Order:
- 1st: Charcoal Swab (Bacteria/Candida) - If needed
- 2nd: NAAT (DNA) - Or first if sole test
- 3rd: pH/Wet Mount - Last
Strawberry Cervix - Detailed
| Aspect | Details |
|---|---|
| Description | Punctate red/hemorrhagic spots on cervix |
| Pathology | Dilated capillaries + micro-hemorrhages |
| Prevalence | Only 2-5% visible to naked eye |
| Colposcopy | Visible in >50% if using colposcope (magnification) |
| Diagnostic Value | Highly specific (Pathognomonic) but low sensitivity |
| Differential | Atrophic vaginitis (post-menopausal) can look similar |
Vaginal pH Interpretation Guide
| pH Value | Interpretation | Potential Diagnosis |
|---|---|---|
| Less than 4.5 | Normal (Acidic) | Physiological, Candida |
| 4.5 - 5.0 | Mildly Elevated | BV, Trichomoniasis |
| 5.0 - 6.0 | Moderately Elevated | Trichomoniasis (Often higher than BV) |
| More than 6.0 | Highly Elevated | Trichomoniasis, Atrophic Vaginitis, DIV |
| More than 7.0 | Neutral/Alkaline | Menses, Semen, Amniotic Fluid |
Key Principle
[!IMPORTANT] Diagnostic Approach: > 1. NAAT (Nucleic Acid Amplification Test) is the Gold Standard (Sensitivity >95%). > 2. Wet Mount Microscopy provides immediate point-of-care diagnosis but has low sensitivity (50-60%) - A negative result does NOT exclude Trichomoniasis. > 3. Vaginal pH > 4.5 supports the diagnosis (but is non-specific).
Diagnostic Tests Comparison
| Test | Sensitivity | Specificity | Turnaround | Advantages | Disadvantages |
|---|---|---|---|---|---|
| NAAT (PCR) | 95-100% | 98-100% | 1-3 days | Gold standard, Highly sensitive, Self-swab | Delayed result |
| Wet Mount | 50-60% | Variable | Immediate | Point-of-care diagnosis, Motility seen | Low sensitivity, Operator dependent |
| Rapid Antigen | 80-90% | 95% | 15 mins | Faster than NAAT | Less sensitive than NAAT |
| Culture | 75-85% | 100% | 3-7 days | Can test for resistance | Slow, Labour intensive |
| pH Testing | Low | Low | Immediate | Supportive evidence | Non-specific (High in BV too) |
NAAT Testing Strategy (Gold Standard)
Sample Sites:
| Patient | Sample Type | Sensitivity |
|---|---|---|
| Women | Vulvovaginal Swab (Self-taken) | 98-100% (Best) |
| Women | Endocervical Swab (Clinician) | 95-98% |
| Women | First Void Urine | 90-95% (Less preferred) |
| Men | First Void Urine | 95-98% (Best) |
| Men | Urethral Swab | High |
Protocol:
- Often included in "Triple Screen" panels (Chlamydia + Gonorrhoea + Trichomonas).
- Can use same swab technology as for CT/NG (e.g. Aptima).
- Window Period: Can detect reliable DNA 4-7 days after exposure.
Wet Mount Microscopy (Point-of-Care)
Procedure:
- Take High Vaginal Swab (HVS) from posterior fornix.
- Place directly into tube of normal saline (0.9%).
- Place drop on slide with cover slip.
- Examine immediately (within 10-15 mins) under phase-contrast (x400).
Findings:
- Trichomonads: Pear-shaped, slightly larger than WBCs.
- Motility: Characteristic jerky / twitching / tumbling motion.
- WBCs: Usually abundant (>10 per HPF).
- Clue Cells: May be present (Concurrent BV).
[!WARNING] Negative Microscopy: If wet mount is negative but symptoms persist or suspicion is high, you MUST send a NAAT. Do not rely solely on microscopy.
Vaginal pH Testing
Procedure:
- Touch pH paper to vaginal wall (mid-vagina).
- Avoid cervical mucus (pH 7.0) or lubricant.
Interpretation:
- Normal: pH Less than 4.5
- Trichomoniasis: pH > 4.5 (Often 5.0-6.0)
- Bacterial Vaginosis: pH > 4.5
- Candida: pH Less than 4.5 (Normal)
Additional Investigations and Screening
Full STI Screen (Recommended for all):
| Test | Rationale |
|---|---|
| Chlamydia NAAT | 10-20% co-infection rate |
| Gonorrhoea NAAT | 10-15% co-infection rate |
| HIV Serology | Trichomoniasis facilitates transmission |
| Syphilis Serology | Routine screen |
| Hepatitis B/C | Based on risk factors |
Speculum Examination Checklist:
- Inspect Vulva: Dermatitis, discharge.
- Insert Speculum: Note discharge characteristics.
- Inspect Cervix: Look for "Strawberry" signs (Colpitis macularis).
- Take Swabs: HVS (pH/Wet mount) + NAAT.
- Bimanual: Check for tenderness (PID).
Why Culture is Rarely Used Now
- InPouch TV System was historic gold standard.
- Requires incubation for up to 7 days.
- Lower sensitivity than modern NAAT.
- Now primarily used for Resistance Testing (sending isolates to reference labs).
Key Principle
[!IMPORTANT] Metronidazole is curative (More than 90% cure rate) Partner notification and treatment essential Avoid alcohol during treatment (Disulfiram reaction)
Management Algorithm

First-Line Treatment - Detailed
| Regimen | Dose | Duration | Cure Rate | Notes |
|---|---|---|---|---|
| Metronidazole | 400mg BD | 5-7 days | More than 95% | First-line, Preferred |
| Metronidazole | 2g stat | Single dose | 85-90% | Alternative (Higher side effects) |
7-Day vs Single Dose Comparison:
| Factor | 7-Day Course | Single Dose |
|---|---|---|
| Cure Rate | More than 95% | 85-90% |
| Adherence | Requires memory | Better compliance |
| Side Effects | Less nausea | More nausea |
| Partner Treated | Both can take course | Both take stat |
| Preferred In | Pregnancy | Non-pregnant, No follow-up |
Second-Line Treatment - Detailed
| Regimen | Dose | Duration | Indication | Notes |
|---|---|---|---|---|
| Tinidazole | 2g stat | Single | Metronidazole failure/intolerance | Better GI tolerance |
| High-Dose Metronidazole | 400mg TDS | 7-14 days | Resistant infection | If low-level resistance |
| Tinidazole | 2g OD | 14 days | Resistant infection | High-level resistance |
| Combined Tinidazole + Intravaginal Metronidazole | Variable | 14 days | Refractory cases | Specialist |
Metronidazole Pharmacokinetics & Interactions
| Parameter | Details | Clinical Implication |
|---|---|---|
| Bioavailability | >90% (Oral) | IV rarely needed |
| Half-life | 8 hours | BD dosing or Stat dose works |
| Metabolism | Hepatic (CYP450) | Caution in severe liver disease |
| Excretion | Renal (60-80%) | Dark urine common |
| Protein Binding | Less than 20% | Good tissue penetration |
Key Drug Interactions:
| Drug | Interaction Type | Consequence | Management |
|---|---|---|---|
| Alcohol | Inhibition of Aldehyde Dehydrogenase | Disulfiram reaction (Vomiting, Flushing) | AVOID during + 48h after |
| Warfarin | CYP2C9 Inhibition | Increased INR (Bleeding risk) | Monitor INR closely; Reduce Warfarin |
| Lithium | Reduced Renal Clearance | Lithium Toxicity | Monitor Lithium levels |
| Phenytoin | Metabolism Inhibition | Phenytoin Toxicity | Monitor levels |
| Cyclosporin | Enzyme Inhibition | Increased Cyclosporin | Monitor levels |
Prescribing in Special Populations (Detailed)
1. Pregnancy:
- First Trimester: Metronidazole 400mg BD for 7 days is safe. Avoid high-dose stat regimens if possible (theoretical risk, though evidence supports safety).
- Second/Third Trimester: Metronidazole 400mg BD for 7 days.
- Preterm Risk: Symptomatic infection must be treated to reduce preterm birth risk.
- Asymptomatic Screening: Not routinely recommended.
2. Breastfeeding:
- Metronidazole is excreted in breast milk.
- Standard Advice: Safe to use. Large doses (2g stat) may cause bitter taste in milk.
- Strategy: Can withhold breastfeeding for 12-24 hours after 2g stat dose if concerned, or use 400mg BD regimen (levels lower).
- British National Formulary (BNF): "Amount too small to be harmful."
3. Renal Impairment:
- CKD 1-3 (eGFR > 30): No dose adjustment needed.
- CKD 4-5 (eGFR Less than 30): No dose adjustment usually needed for short course, but monitor for metabolites.
- Dialysis: Metronidazole is removed by dialysis. Administer dose after dialysis session.
4. Hepatic Impairment:
- Mild/Moderate: No adjustment.
- Severe (Child-Pugh C): Reduce dose by 50% or increase interval (e.g. 400mg OD), as metabolism is slowed.
5. Metronidazole Allergy:
- True allergy (anaphylaxis) is rare but challenging.
- Alternatives:
- Tinidazole: Often cross-reactivity exists (contraindicated).
- Desensitisation: Oral desensitisation protocols available in specialist centres.
- Non-Nitroimidazole agents: Paromomycin (intravaginal) or high-dose Clotrimazole have very low cure rates (Less than 50%) and are not recommended unless absolute necessity.
- Referral: All true allergy cases require GUM Specialist management.
Metronidazole Counselling - Detailed
Essential Counselling Points:
| Point | What to Say |
|---|---|
| Complete Course | "Take all the tablets even if you feel better" |
| Timing | "Take with food to reduce stomach upset" |
| No Alcohol | "No alcohol for 48 hours after finishing" |
| Alcohol Reaction | "Alcohol will make you very sick (Vomiting, Flushing, Headache)" |
| Side Effects | "You may notice nausea, Metallic taste – These are normal" |
| Partner Treatment | "Your partner must be treated too" |
| No Sex | "Avoid sex until both have finished treatment + 7 days" |
| Follow-Up | "Come back if symptoms don't improve" |
Sample Counselling Script (OSCE):
"I'm prescribing you an antibiotic called Metronidazole. You'll take one tablet twice a day for 7 days. It's very important that you take all the tablets, Even if you feel better. There's one very important thing – You must NOT drink any alcohol while taking these tablets, And for 48 hours after finishing. If you do, You'll become very unwell with severe vomiting, Flushing, And headaches. Common side effects include nausea and a metallic taste, Which are normal. Your partner must be treated at the same time, Even if they have no symptoms. You should both avoid sex until 7 days after you've both finished treatment. Does that all make sense? Any questions?"
Partner Notification - Detailed
| Aspect | Details |
|---|---|
| Essential | Partner treatment mandatory to prevent reinfection |
| Method: Patient Referral | Patient tells partner to attend |
| Method: Provider Referral | Healthcare contacts partner (With consent) |
| Method: Contact Slip | Patient gives slip to partner |
| Epidemiological Treatment | Treat partner without testing |
| Lookback Period | Current partner(s) |
| Avoid Sex | Until both completed treatment + 7 days |
Partner Notification Counselling:
| Point | What to Say |
|---|---|
| Why | "Your partner needs treatment to stop you getting reinfected" |
| Even if No Symptoms | "Many people have no symptoms but can still pass it on" |
| How to Tell Them | "Would you prefer to tell them, Or would you like us to contact them?" |
| Contact Slip | "Give them this slip – They can attend any sexual health clinic" |
| Timing | "Please tell them as soon as possible" |
Test of Cure
| Indication | When | Method |
|---|---|---|
| Persistent Symptoms | 2 weeks after treatment | NAAT |
| Pregnancy | 1 month after treatment | NAAT |
| High Reinfection Risk | 3 months | NAAT |
| Routine (Asymptomatic) | Not required | - |
| Treatment Failure Suspected | 2 weeks | NAAT + Culture |
Management of Treatment Failure (Step-by-Step)
If symptoms persist or test remains positive:
Step 1: Check Compliance & Sexual History (The Basics)
- Adherence: Did they take the pills? (Did they vomit?)
- Timing: Did they complete the course?
- Alcohol: Did they stop alcohol (avoiding vodka-vomiting)?
- Re-exposure: Did they have sex? Was partner treated? (Most common cause)
Step 2: Reinfection vs Relapse
- Reinfection: Most likely (>90%). New exposure or untreated partner.
- Action: Retreat with standard course (Metronidazole 400mg BD x 7 days).
- Partner: Ensure partner is treated (Supervised therapy if needed).
- Relapse: Persistence despite adherence and no re-exposure.
- Action: Suspect resistance or poor absorption.
Step 3: Empiric Second-Line (If compliance confirmed)
- Regimen: Metronidazole 400mg TDS for 7 days (UK) or Tinidazole 2g single dose.
- Alternative: Tinidazole 500mg QDS for 1 week (High dose).
- Note: High dose metronidazole/tinidazole has more side effects (nausea, neurotoxicity).
Step 4: Refractory / Resistant Cases
- Definition: Failure of nitroimidazole treatment after excluding reinfection/non-compliance.
- Action:
- Culture: Swab for Culture and Sensitivity (Reference Lab).
- Specialist Management: Referral to GUM consultant.
- High Dose Tinidazole: 1g BD or TDS for 14 days (Specialist only).
- FemCure Trial Regimens: Dequalinium Chloride (10mg PV OD x 6 days) – Shows promise.
- Paromomycin: Intravaginal cream (Poor efficacy, side effects).
- Boric Acid: Low cure rate, salvage only.
[!WARNING] Metronidazole Resistance:
- Rare (Less than 5%) but increasing worldwide.
- Mechanisms involve reduced nitroreductase activity in the hydrogenosome.
- Do not keep repeating the same failing dose. Escalate to specialist.
Alternative / Natural Remedies (Facts and Myths)
Patients frequently ask about non-antibiotic treatments. It is important to be clear:
| "Remedy" | Efficacy | Clinical Advice |
|---|---|---|
| Vaginal Douching | Harmful | Increases risk of PID, BV, and ectopic pregnancy. Pushes bacteria up. Do not use. |
| Tea Tree Oil | Minimal/Unknown | Can cause severe chemical dermatitis/burns. Not recommended. |
| Probiotics | Supportive only | Good for restoring flora post-antibiotic (Lactobacillus), but does not cure Trichomoniasis. |
| Garlic (PV) | None | No evidence. Can cause chemical burns to mucosa. |
| Cranberry Juice | None | Useful for UTIs (anti-adhesion), useless for vaginal trichomoniasis. |
| Boric Acid | Low | Sometimes used as salvage for resistant cases, but cure rates are low (Less than 40%). |
| Yoghurt | None | Soothing for Candida, useless for Trichomonas. |
[!TIP] Counselling Tip: "This is a parasite that 'swims'. Flushing it with water or using herbal remedies won't kill it. You need the specific antibiotic that stops its engine (hydrogenosome) working."
Follow-Up Strategy
| Indication | Action | Timeframe |
|---|---|---|
| Asymptomatic after Treatment | No follow-up needed | - |
| Persistent Symptoms | Re-test (NAAT/Culture) | 2 weeks post-treatment |
| Pregnancy | Test of Cure (TOC) | 1 month post-treatment |
| High Risk of Reinfection | Rescreen | 3 months |
| Vomited Medication | Repeat dose | Immediate |
| Factor | Details |
|---|---|
| Prevalence | Less than 5% in UK |
| Increasing | Emerging concern |
| Testing | Specialised centres |
| Management | Higher doses, Longer courses, Tinidazole |
OSCE Station: Trichomoniasis Counselling
Expected Competencies:
| Task | What to Do |
|---|---|
| Explain Diagnosis | "You have an infection called Trichomoniasis" |
| Cause | "It's caused by a tiny parasite passed on during sex" |
| Treatment | "Antibiotic tablets for 7 days" |
| Alcohol Warning | "Absolutely no alcohol for 48 hours after finishing" |
| Partner Treatment | "Your partner must be treated too" |
| Avoid Sex | "Both avoid sex until 7 days after treatment finished" |
| Follow-Up | "Come back if symptoms don't go" |
| Check Understanding | "Can I check you understand?" |
Overview
| Category | Complications | Frequency |
|---|---|---|
| Reproductive | PID, Infertility | Rare but possible |
| Pregnancy | Preterm birth, PROM, Low birth weight | Significant (1.4x risk) |
| Infectious | HIV Acquisition, HIV Transmission | 1.5-2x risk |
| Male | Prostatitis, Epididymitis, Urethritis | Uncommon |
| Psychological | Anxiety, Relationship breakdown | Common |
Pregnancy Complications - Detailed Mechanisms
Preterm Birth and Low Birth Weight:
- Risk: 1.4-1.8x increased risk of preterm delivery (Less than 37 weeks).
- Mechanism:
- T. vaginalis produces proteases that degrade the chorioamniotic membrane.
- Induces local inflammation (IL-8, Prostaglandins).
- Prostaglandins trigger uterine contractions.
- Weakening of membranes leads to PROM (Premature Rupture of Membranes).
Implication for Management:
- Symptomatic pregnant women MUST be treated.
- Screening asymptomatic pregnant women is controversial (some studies suggested treatment might increase PTB, but recent guidelines suggest treating).
The HIV Synergy (Public Health Critical)
1. Increased Acquisition (Getting HIV):
- T. vaginalis causes microscopic ulcerations in the epithelium.
- It recruits CD4+ T-cells (HIV targets) to the vaginal/cervical mucosa.
- Result: An HIV-negative person with Trichomoniasis is 1.5-2 times more likely to acquire HIV if exposed.
2. Increased Transmission (Passing HIV):
- In HIV-positive individuals, Trichomoniasis increases genital viral shedding.
- Result: An HIV-positive person with Trichomoniasis is more infectious to their partners.
[!IMPORTANT] Conclusion: Effective control of Trichomoniasis is a crucial HIV prevention strategy.
Pelvic Inflammatory Disease (PID)
- T. vaginalis is an independent risk factor for PID.
- Can transport bacteria into the upper genital tract ("Trojan Horse" effect).
- Presentation: Pelvic pain, deep dyspareunia.
- Management: If PID suspected, treat for PID (covering GC/CT/Anaerobes) + add Metronidazole for TV.
Male Complications (Under-recognised)
| Condition | Mechanism |
|---|---|
| NGU (Non-Gonococcal Urethritis) | 10-20% of NGU cases are caused by TV |
| Chronic Prostatitis | Parasite can colonise the prostate gland |
| Epididymitis | Ascending infection |
| Infertility | Reduced sperm motility, agglutination |
Treatment Efficacy
| Regimen | Cure Rate | Relapse Rate |
|---|---|---|
| 7-Day Metronidazole | 95-98% | Low |
| Single Dose Metronidazole | 85-90% | Moderate (Higher failure) |
| Tinidazole | 90-95% | Low |
| No Treatment | 20-30% spontaneous resolution | 70% persistence (Chronic) |
Prognostic Factors
Good Prognosis Indicators:
- Adherence to 7-day course.
- Partner simultaneously treated.
- Sexual abstinence during treatment.
- No co-infections.
Poor Prognosis Indicators:
- Co-infection (Bacterial Vaginosis).
- Untreated partner (Reinfection is #1 cause of "failure").
- HIV infection (May require longer course).
- Non-adherence (Alcohol use, Nausea).
Reinfection vs Resistance
Reinfection (Common):
- Occurs in ~17% of women within 3 months.
- Usually due to resumption of sex with untreated partner.
- Management: Retreatment + Strict partner notification.
Resistance (Rare):
- Occurs in Less than 5% of cases.
- Mechanism: Altered metabolic pathways (reduced nitroreductase activity in hydrogenosome).
- Classification:
- Low-level: Responds to higher dose Metronidazole.
- High-level: Requires Tinidazole or specialist regimens.
Long-Term Sequelae
- No protective immunity: Patients can get Trichomoniasis multiple times.
- No chronic carrier state (after cure): Once cured, the parasite is gone.
- Fertility: Usually preserved if no PID.
Key Guidelines Summary
| Guideline | Organisation | Year | Key Recommendations |
|---|---|---|---|
| BASHH United Kingdom National Guideline | BASHH (UK) | 2021 | 7-day Metronidazole 400mg BD is first-line. Single dose is second-line. Partner notification is mandatory. |
| STI Treatment Guidelines | CDC (USA) | 2021 | 7-day Metronidazole 500mg BD for women. Single dose 2g for men. |
| European Guideline | IUSTI (Europe) | 2021 | Align with BASHH. Emphasises NAAT diagnosis. |
| WHO STI Guidelines | WHO (Global) | 2021 | Syndromic management often used in low-resource settings. |
Landmark Trials & Evidence
1. Seven-Day vs Single-Dose Metronidazole (Kissinger et al., 2018)
- Study Type: Multicentre, open-label, RCT.
- Population: Women with Trichomoniasis (n=623).
- Intervention: Metronidazole 500mg BD x 7 days vs 2g Single Dose.
- Outcome: Treatment failure at 4 weeks.
- Results:
- 7-day Group Failure: 10.6%
- Single Dose Group Failure: 19.7%
- Relative Risk: Single dose failure risk RR = 1.87.
- Conclusion: 7-day course is significantly superior.
- Clinical Impact: Changed CDC and BASHH guidelines to prefer 7-day course for women.
- PMID: 30281989 (Link)
2. Treating Trichomoniasis in HIV (Kissinger et al., 2015)
- Study Type: RCT.
- Result: Treating T. vaginalis in HIV-positive women reduces genital HIV RNA shedding.
- Implication: Treatment functions as "Treatment as Prevention" for HIV.
- PMID: 26242185
3. Preterm Birth and Metronidazole (Klebanoff et al., 2001)
- Study Type: Large RCT.
- Finding: Treating asymptomatic Trichomoniasis in pregnancy did NOT reduce preterm birth (and might have slightly increased it in some subgroups).
- Nuance: This refers to asymptomatic screening. Symptomatic women must always be treated.
- PMID: 11516431
4. Partner Treatment Efficacy (Seña et al., 2007)
- Finding: Partner notification and treatment reduces recurrence rates by >75%.
- Implication: Treat the partner or the patient will return.
5. NAAT vs Culture vs Wet Mount (Hobbs et al., 2013)
- Study: Comparison of diagnostic methods.
- Sensitivity Data:
- Wet Mount: 51%
- Culture: 75%
- Aptima TV (NAAT): 98%
- Conclusion: Microscopy misses half of all cases. NAAT is essential.
- PMID: 23392437
Guideline Discordance Areas
| Issue | BASHH (UK) | CDC (USA) | Explanation |
|---|---|---|---|
| Treatment for Men | 7-day course preferred | Single dose 2g preferred | CDC prioritises adherence in men; BASHH prioritises efficacy. |
| Screening in Pregnancy | Symptomatic only | Symptomatic only | Both agree asymptomatic screening not routinely recommended. |
| Follow-Up | No TOC if asymptomatic | Rescreen at 3 months | CDC aggressive on re-screening due to high reinfection rates in US. |
Evolving Evidence: Resistance
- Prevalence: Currently low (Less than 5%) but rising.
- Mechanism: Downregulation of biological activation of metronidazole.
- Testing: Only at specialist centres (e.g., CDC, reference labs).
- New Drugs: Secnidazole (single dose 2g) FDA approved (2017) – similar to metronidazole but longer half-life.
What is Trichomoniasis?
Trichomoniasis (or "Trich") is a very common sexually transmitted infection (STI). It is caused by a tiny parasite (not a bacteria or virus).
- It is very common: Millions of people get it every year.
- It is easily treated: Antibiotics usually cure it completely.
- It is not dangerous (mostly): But it can cause problems in pregnancy if untreated.
Signs and Symptoms
In Women: Most women (about 7 in 10) have symptoms:
- Discharge: It might be yellow or green, frothy, and have a strong, fishy smell.
- Itching: Soreness or severe itching around the vagina.
- Pain: Discomfort when passing urine or during sex.
In Men: Most men (9 in 10) have NO symptoms. They carry the parasite without knowing.
- Occasionally: Mild discharge or irritation inside the penis.
- Risk: Because they feel fine, they pass it on unknowingly.
How is it Treated?
The treatment is an antibiotic called Metronidazole.
- usually taken twice a day for 7 days.
- Sometimes given as a single large dose.
⚠️ IMPORTANT: The "No Alcohol" Rule
You MUST NOT drink any alcohol while taking these tablets, and for 48 hours (2 days) after finishing the course.
| If you drink Alcohol... | What will happen? |
|---|---|
| Even a small amount | Severe reaction |
| Reaction | Violent vomiting, Flushing (face goes red), Thumping headache, Racing heart |
| Duration | Can aid serious illness |
| Safety | Just wait 48 hours to be safe! |
Partner Notification: The Hard Part
You must tell your sexual partner(s). Even if they feel 100% fine.
- If they are not treated, they will pass it straight back to you.
- Then you will need to take the antibiotics again!
How to say it:
"I've just been diagnosed with an infection called Trichomoniasis. It's easily treated with tablets, but you need to get treated too, even if you have no symptoms. Please go to a clinic this week."
Myth Buster
| Myth | Fact |
|---|---|
| "He has no symptoms, so he's clean." | FALSE. Men rarely have symptoms but still carry and spread it. |
| "I can wash it away." | FALSE. Douching makes it worse by changing vaginal balance. |
| "I can catch it from a toilet seat." | FALSE. The parasite dies quickly outside the body. It is from sex. |
| "One pill is enough." | FALSE. The 7-day course is much better at destroying the parasite. |
| "I can drink one glass of wine." | FALSE. Even mouthwash with alcohol can sometimes trigger the reaction! |
Frequently Asked Questions (FAQs)
Q: Will it affect my fertility? A: Generally no. Unlike Chlamydia or Gonorrhoea, it rarely damages the tubes. However, treating it creates a healthier environment for conception.
Q: Can I have sex during treatment? A: No. You should wait until you AND your partner have finished the tablets, plus 7 days. This allows the medication to work and ensures you don't pass it back and forth.
Q: I'm pregnant. Is the baby safe? A: Untreated trichomoniasis is linked to having the baby too early (preterm birth). Treating it reduces the infection, although the link to outcomes is complex. The antibiotic metronidazole is generally considered safe in pregnancy.
Q: How did I get it? I haven't had sex in months. A: In some cases, the infection can be present for months or even years without causing major symptoms, then suddenly "flare up." So it doesn't always prove a partner has cheated recently.
When to Seek Help Urgently
Go back to your doctor if:
- You vomit the tablets up (you might need a re-dose).
- Symptoms don't go away after the course.
- You develop severe lower tummy pain or fever (could be a deeper infection).
Primary Guidelines
- Sherrard J, et al. 2021 UK National Guideline on the Management of Trichomonas vaginalis. British Association for Sexual Health and HIV (BASHH). 2021. Available at: BASHH
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. 4):1–187. DOI: 10.15585/mmwr.rr7004a1
- Tiplica GS, et al. 2021 European Guideline on the Management of Trichomonas vaginalis. International Union against Sexually Transmitted Infections (IUSTI). 2021.
- World Health Organization. Guidelines for the management of symptomatic sexually transmitted infections. Geneva: WHO; 2021. ISBN: 978-92-4-002416-8.
Key Evidence & Trials
- Kissinger P, Muzny CA, Mena LA, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(11):1251-1259. PMID: 30281989
- Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev. 2003;(2):CD000218. PMID: 12804383
- Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis. 2015;15:307. PMID: 26242185
- Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med. 2001;345(7):487-493. PMID: 11516431
- Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007;44(1):13-22. PMID: 17143809
Epidemiology & Pathogenesis
- Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548-562P.
- Hirt RP, Sherrard J. Trichomonas vaginalis origins, molecular pathobiology and clinical considerations. Curr Opin Infect Dis. 2015;28(1):72-79.
- Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev. 2004;17(4):794-803.
Diagnostics
- Hobbs MM, Seña AC. Modern diagnosis of Trichomonas vaginalis infection. Sex Transm Infect. 2013;89(6):434-438.
- Van Der Pol B, et al. Performance of the Aptima Trichomonas vaginalis assay for detection of Trichomonas vaginalis in men and women. J Clin Microbiol. 2016;54(1):7-12.
- Nathan B, et al. Microscopy in the diagnosis of Trichomonas vaginalis. Int J STD AIDS. 2015;26(5):351-354.
Complications & HIV
- McClelland RS, Sangaré L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007;195(4):569-577.
- Mavedzenge SN, Van Der Pol B, Weiss HA. The association between Mycoplasma genitalium and HIV-1 acquisition in African women. AIDS. 2012;26(5):617-624. [Evidence review of co-infections]
- Silver BJ, Guy RJ, Kaldor JM, et al. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review. Sex Transm Dis. 2014;41(6):369-376.
Review Articles
- Sobel JD. Trichomoniasis: What's new? Expert Rev Anti Infect Ther. 2017;15(12):1113-1116.
- Muzny CA, et al. The clinical spectrum of Trichomonas vaginalis infection in men. Clin Infect Dis. 2014;58(2):299-300.
- Meites E, et al. A review of evidence-based care of symptomatic trichomoniasis. Clin Infect Dis. 2015;61(Suppl 8):S837-S848.
Glossary of Terms
| Term | Definition |
|---|---|
| Amine Odour | A "fishy" smell produced by amines (e.g., putrescine, cadaverine) when vaginal pH increases, often intensified by adding KOH (Whiff test). |
| Axostyle | A rigid, microscopic rod-like structure running through the Trichomonas cell, involved in attachment to host cells. |
| Colpitis Macularis | The medical term for "strawberry cervix" – punctate hemorrhages on the cervix seen in Trichomoniasis. |
| Dyspareunia | Pain during or after sexual intercourse. Deep dyspareunia suggests pelvic involvement; superficial suggests vulvitis. |
| Flagellum | A microscopic whip-like appendage that enables many protozoa and bacteria to swim. T. vaginalis has four anterior and one posterior flagella. |
| Fomite | An inanimate object (e.g., damp towel) that can theoretically transmit infection, though extremely rare for T. vaginalis. |
| Hydrogenosome | A specialised organelle found in T. vaginalis (instead of mitochondria) that produces hydrogen and ATP anaerobically; the target site for metronidazole. |
| Incubation Period | The time from sexual exposure to the onset of symptoms, typically 4-28 days for Trichomoniasis. |
| Metronidazole | A nitroimidazole antibiotic used to treat anaerobic bacteria and protozoa. It requires reduction in the organism to become active. |
| NAAT | Nucleic Acid Amplification Test. A diagnostic technique (like PCR) that amplifies minute amounts of DNA/RNA to detect pathogens. Gold standard for Trichomoniasis. |
| Nitroimidazole | The class of antibiotics to which metronidazole and tinidazole belong. |
| Protozoan | A diverse group of unicellular eukaryotic organisms. Trichomonas is a protozoan (not a bacteria, virus, or fungus). |
| Reservoir | A host who carries the pathogen often without symptoms, maintaining the infection chain (Asymptomatic men are the key reservoir). |
| Trophozoite | The active, feeding stage of a protozoan parasite. T. vaginalis exists only in this form (no cyst stage). |
| Undulating Membrane | A fin-like extension of the cell membrane in Trichomonas that aids in motility ("wobbly" swimming). |
| Urethritis | Inflammation of the urethra, often caused by STIs like Trichomonas, causing dysuria and discharge. |
| Wet Mount | A microscopic examination of fresh vaginal discharge mixed with saline to visualize motile organisms. |
| Whiff Test | A clinical test where potassium hydroxide (KOH) is added to vaginal discharge; a fishy odour indicates amines (Positive in BV and Trichomoniasis). |
High-Yield Facts for Exams
| Fact | Value | Exam Importance |
|---|---|---|
| Organism | Protozoan (Flagellated) | Critical – NOT bacteria/virus |
| Classic Discharge | Frothy, Yellow-green, Malodorous | "Frothy" is the key buzzword |
| Pathognomonic Sign | Strawberry cervix (Colpitis macularis) | "Strawberry" = Trichomoniasis |
| Diagnosis | NAAT (Gold Standard) | Replaces culture |
| Microscopy | Motile protozoa ("Twitching") | Classic wet mount finding |
| pH Finding | More than 4.5 (Alkaline) | Same as BV |
| Whiff Test | Positive (Amine/Fishy) | Same as BV |
| First-Line Treatment | Metronidazole 400mg BD x 7 days | Better than single dose |
| Interaction | Disulfiram-like with Alcohol | "Antabuse reaction" |
| Partner Treatment | Mandatory (Even if asymptomatic) | Public health critical |
| HIV Link | Increases acquisition (1.5-2x) | Important complication |
"Buzzword Bingo"
| Buzzword | Diagnosis/Association |
|---|---|
| "Frothy discharge" | Trichomoniasis |
| "Yellow-green discharge" | Trichomoniasis |
| "Strawberry cervix" | Trichomoniasis |
| "Flagellated organism" | Trichomoniasis |
| "Motile protozoa" | Trichomoniasis |
| "Punctate cervical hemorrhages" | Trichomoniasis |
| "Clue cells" | Bacterial Vaginosis (NOT Trich) |
| "Pseudohyphae" | Candida (NOT Trich) |
Common Exam Questions
Question 1 (SBA): A 24-year-old woman presents with offensive vaginal discharge. Speculum examination reveals a "strawberry cervix" with punctate hemorrhages. The vaginal pH is 5.5. What is the most likely causative organism? A. Candida albicans B. Gardnerella vaginalis C. Trichomonas vaginalis D. Neisseria gonorrhoeae E. Chlamydia trachomatis Answer: C (Pathognomonic sign + pH >4.5)
Question 2 (SBA): A 30-year-old woman is prescribed metronidazole for trichomoniasis. What specific advice must be given regarding alcohol consumption? A. Avoid alcohol for 1 hour after taking B. Alcohol decreases the efficacy of the drug C. Avoid alcohol during treatment and for 48 hours after D. Alcohol causes sedation with this drug E. No specific advice needed Answer: C (Disulfiram-like reaction: Flushing, Vomiting)
Question 3 (SBA): Which of the following complications is most strongly associated with untreated trichomoniasis in pregnancy? A. Congenital malformations B. Preterm delivery and low birth weight C. Neonatal conjunctivitis D. Neonatal pneumonia E. Hydrops fetalis Answer: B (Preterm delivery risk increased 1.4-1.8x)
OSCE Station: STI Counselling
Scenario: "Sarah, 23, has just been diagnosed with Trichomoniasis via a swab taken 3 days ago. She is currently asymptomatic. Please explain the diagnosis, management plan, and partner notification requirements."
Mark Scheme:
| Domain | Competency | Marks |
|---|---|---|
| Introduction | Introduce self, check identity, check understanding | 2 |
| Diagnosis | Explain "Trichomoniasis" clearly (STI, Parasite) | 2 |
| Reassurance | "It is very common and easily treated" | 1 |
| Treatment | Antibiotics (Metronidazole) 1 week course | 2 |
| Safety Netting | ALCOHOL WARNING (Crucial fail point if missed) | 3 |
| Side Effects | Nausea, Metallic taste | 1 |
| Partner Notification | Explain need to treat current partner | 3 |
| Sexual Abstinence | No sex until both treated + 7 days | 2 |
| Follow-Up | Advise return if symptoms persist | 1 |
| HIV Testing | Offer HIV test (Standard of care) | 2 |
| Closing | Summarise, check understanding, leaflet | 1 |
| Total | 20 |
Viva Points
Candidate Opening Statement:
"Trichomoniasis is a sexually transmitted infection caused by the flagellated protozoan Trichomonas vaginalis. It has a global incidence of over 150 million cases annually. Clinically, it presents with vulvitis and a characteristic frothy yellow-green discharge, though men are often asymptomatic reservoirs. Management involves 7 days of metronidazole, strict alcohol avoidance, and simultaneous partner treatment to prevent reinfection."
Examiner: "Why is the 7-day course preferred over the single dose?"
Candidate: "Meta-analyses (Cochrane) show the 7-day course has significantly higher cure rates (>95% vs ~85%) and lower reinfection rates compared to the 2g single dose. It is the recommended first-line treatment in UK (BASHH) and US (CDC) guidelines."
Examiner: "What is the mechanism of the alcohol reaction?"
Candidate: "Metronidazole inhibits the enzyme aldehyde dehydrogenase. This causes an accumulation of acetaldehyde when alcohol is consumed, leading to the 'disulfiram-like' reaction of flushing, tachycardia, nausea, and vomiting."
Common Mistakes to Avoid
| Mistake | Correction |
|---|---|
| ❌ "It's bacteria" | ✅ It is a PROTOZOAN PARASITE |
| ❌ "Treat only if symptoms" | ✅ Treat asymptomatic partners to stop spread |
| ❌ "Can drink a little" | ✅ Zero alcohol tolerance advised |
| ❌ "Single dose is best" | ✅ 7-day course is superior (Gold standard) |
| ❌ "It's harmless" | ✅ Linked to HIV acquisition and preterm birth |
Clinical Reasoning Scenarios
Scenario A: Recurrent Symptoms
- Situation: Patient treated 3 weeks ago returns with same symptoms.
- Reasoning:
- Adherence: Did she take the pills? (And avoid alcohol/vomiting?)
- Reinfection: Did partner get treated? Did they have sex too soon? (Most common)
- Resistance: Rare, but possible.
- Action: Retreatment (often higher dose) + STRICT partner management.
Scenario B: Pregnancy
- Situation: 10 weeks pregnant, symptomatic.
- Reasoning: Metronidazole generally safe, but avoid high stat doses in 1st trimester.
- Action: Treat with standard 5-7 day course. Symptomatic relief outweighs theoretical risks.
Dangerous Errors (Automatic Fail)
[!CAUTION] OSCE Fail Points: > 1. Failing to warn about Alcohol interaction (Patient safety). > 2. Failing to address Partner notification (Public health). > 3. Dismissing symptoms in Pregnancy (Fetal risk).
Last Reviewed: 2025-12-25 | MedVellum Editorial Team
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.